Comparative Clinical Trial of Recombinant Human Endostatin Combined with FOLFOX4 Regimen in the Treatment of Advanced Colorectal Cancer

Chuanqi HE,Zheng WANG,Jinxian CHEN
DOI: https://doi.org/10.3969/j.issn.1008-7125.2009.08.002
2009-01-01
Abstract:Background: Both pre-clinical and clinical studies indicated that recombinant human endostatin (rh-endostatin) could inhibit endothelial cell proliferation, angiogenesis, tumor growth and with security assurance in clinical use. Aims: To assess the response rate (RR), clinical benefit rate (CBR), median time to progression (TTP) and progression rate of advanced colorectal cancer (ACRC) patients treated with rh-endostatin plus FOLFOX4 regimen, and to observe the improvement in quality of life (QOL) and adverse effects. Methods: Fifty histologically proven stage IV, initial treatment or retreatment ACRC patients with Karnofsky Performance Status (KPS) ≥60 were randomly allocated to treatment group or control group. The treatment group (25 patients) received rh-endostatin (7.5 mg/m2 on day 1 to 14) plus FOLFOX4 regimen, while the control group were receiving FOLFOX4 regimen plus placebo (normal saline, with the same dosage as rh-endostatin). Results: Of the 50 assessable patients, overall RR, CBR, median TTP and improvement of QOL in treatment group (44.0%, 76.0%, 7.8 months and 64.0%) were much higher than those in control group (16.0%, 48.0%, 5.0 months and 36.0%, P=0.062, 0.041, 0.040 and 0.048, respectively), whereas the progression rate of tumor was much lower in the treatment group (P<0.05). In untreated ACRC patients, RR, CBR and median TTP in treatment group were significantly increased than those in control group (P<0.05); whereas in previously treated ACRC patients, no significant difference was observed between these two groups. There were no significant differences in adverse effects between these two groups. Conclusions: rh-endostatin plus FOLFOX4 regimen is safe and can significantly improve RR, median TTP and QOL as compared with FOLFOX4 alone in ACRC, especially untreated ACRC patients.
What problem does this paper attempt to address?